Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04202965 · ClinicalTrials.gov registry record · Phase 2
PTG-300 in Subjects With Hereditary Hemochromatosis
A Phase 2 study, sponsored by Protagonist Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04202965 is a Phase 2 study that has completed, run by Protagonist Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT04202965, a Phase 2 study, has completed, sponsored by Protagonist Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.
Interventions
- DRUG PTG-300
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-03-19 |
| Est. Completion | 2022-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04202965
The ClinicalTrials.gov registry entry for NCT04202965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protagonist Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTG-300 is the first listed.
NCT04202965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04202965 about?
NCT04202965 is a clinical study titled "PTG-300 in Subjects With Hereditary Hemochromatosis". This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.
What is the current status of trial NCT04202965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2020-03-19. Estimated completion is 2022-02-15.
What interventions are being tested in trial NCT04202965?
The interventions under investigation include: PTG-300 (DRUG).
Who is sponsoring clinical trial NCT04202965?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.